KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutanix (NTNX) Cash & Equivalents (2016 - 2026)

Nutanix (NTNX) has disclosed Cash & Equivalents for 11 consecutive years, with $780.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 8.85% to $780.4 million in Q4 2025 year-over-year; TTM through Oct 2025 was $780.4 million, a 8.85% increase, with the full-year FY2024 number at $655.7 million, up 27.83% from a year prior.
  • Cash & Equivalents was $780.4 million for Q4 2025 at Nutanix, down from $872.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $1.1 billion in Q1 2025 to a low of $277.9 million in Q2 2021.
  • A 5-year average of $535.5 million and a median of $480.6 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 30.21% in 2021, then skyrocketed 78.65% in 2025.
  • Nutanix's Cash & Equivalents stood at $354.2 million in 2021, then skyrocketed by 35.69% to $480.6 million in 2022, then rose by 27.43% to $612.5 million in 2023, then rose by 17.07% to $717.0 million in 2024, then grew by 8.85% to $780.4 million in 2025.
  • Per Business Quant, the three most recent readings for NTNX's Cash & Equivalents are $780.4 million (Q4 2025), $872.6 million (Q2 2025), and $1.1 billion (Q1 2025).